After contracting Q Fever in Afghanistan, Phil Eaglesham fell into despair – but assistance dog Cooper helped give him his ...
TUCSON, Ariz. (13 News) - A rare disease forced Vail veteran Christina “Risti” Keith to retire from the Air Force. Now, she’s found a new partner - and freedom - with “Lion.” “He’s a super dog,” Keith ...
EMERYVILLE, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with ...
Drop head syndrome (DHS), characterized by pronounced cervical ventroflexion, is a clinical syndrome that can be found associated with neuromuscular disorders, particularly myasthenia gravis. In this ...
World Myasthenia Gravis Day is celebrated every June 15 th. Myasthenia gravis (MG) is an autoimmune illness that affects approximately 1.5 to 2 million people globally. The disorder is characterized ...
May 2, 2025 -- The FDA has approved a new treatment for generalized myasthenia gravis (gMG), a disease that causes severe muscle weakness, faster muscle fatigue, and difficulty in speaking and ...
Efgartigimod significantly improves MG-ADL and QMG scores in generalized myasthenia gravis, with early responses linked to shorter disease duration and severe bulbar symptoms. Early responders often ...
Adam Taylor does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond their ...
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on Tuesday shared data from the Phase 3 NIMBLE trial assessing investigational cemdisiran monotherapy in adults with generalized myasthenia gravis (gMG).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback